| Human immunodeficiency virus I infection
Fuzeon vs Symtuza
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Fuzeon vs Symtuza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSymtuza has a higher rate of injection site reactions vs Fuzeon based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Symtuza but not Fuzeon, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fuzeon
Symtuza
At A Glance
SC injection
Twice daily
HIV-1 fusion inhibitor
Oral
Once daily
Protease inhibitor + CYP3A inhibitor + NRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Human immunodeficiency virus I infection One tablet orally once daily with food in adults and pediatric patients weighing at least 40 kg (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide).
Contraindications
- Known hypersensitivity to enfuvirtide or any excipient of FUZEON
- Alfuzosin co-administration
- Carbamazepine, phenobarbital, or phenytoin co-administration
- Colchicine in patients with renal and/or hepatic impairment
- Rifampin co-administration
- Lurasidone or pimozide co-administration
- Dronedarone, ivabradine, or ranolazine co-administration
- Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine) co-administration
- St. John's wort co-administration
- Elbasvir/grazoprevir co-administration
- Lomitapide, lovastatin, or simvastatin co-administration
- Naloxegol co-administration
- Sildenafil when used for pulmonary arterial hypertension
- Orally administered midazolam or triazolam co-administration
Adverse Reactions
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Most common (>=2%) Diarrhea, rash, nausea, fatigue, headache, abdominal discomfort, flatulence
Serious Severe acute exacerbations of hepatitis B, hepatotoxicity, severe skin reactions, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Redistribution of body fat, rhabdomyolysis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, crystal nephropathy, crystalluria
Pharmacology
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
Symtuza is a fixed-dose combination containing darunavir (an HIV-1 protease inhibitor that prevents cleavage of Gag-Pol polyproteins), cobicistat (a CYP3A inhibitor that enhances darunavir exposure), emtricitabine (an NRTI that inhibits HIV reverse transcriptase through chain termination), and tenofovir alafenamide (an NRTI prodrug converted to tenofovir diphosphate that inhibits HIV reverse transcriptase).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fuzeon
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
Symtuza
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Fuzeon
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
Symtuza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Fuzeon
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Symtuza
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuzeonView full Fuzeon profile
SymtuzaView full Symtuza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.